Table 1 Data comparisons in different groups of DTC* patients with positive TgAb* at the moment of their first 131I ablation.

From: Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody

Group#

Age

MK*

TgAb*

Tg*@

FT3*

FT4*

TSH*

(Case number)

(years old)

(255.01 ± 126.78 pg/ml23)

(0–40.00 IU/mL)

(0–55.00 ng/mL)

(3.50–6.50 mol/L)

(11.50–23.50 pmol/L)

(0.30–5.00 μIU/mL)

Group 1 (28)

47.43 ± 14.62

836.36 ± 395.10

299.26 ± 425.53

1.64 ± 2.76

1.95 ± 0.79

5.30 ± 1.98

88.25 ± 40.56

Group 2 (123)

47.39 ± 11.37

362.75 ± 246.45

238.60 ± 409.55

0.75 ± 2.20

2.07 ± 1.31

5.44 ± 3.36

94.62 ± 38.72

T value^

0.150

8.098

0.702

1.848

−0.474

−0.203

−0.779

P value^

0.988

<0.001

0.484

0.067

0.636

0.840

0.437

  1. #Group 1 = 131I-avid metastases exist, group 2 = successful ablation without metastases.
  2. *DTC = differentiated thyroid cancer, TgAb = thyroglobulin antibody, MK = midkine, Tg = thyroglobulin, FT3 = free triiodothyronine, FT4 = free thyroxine, TSH = thyroid stimulating hormone.
  3. ^analyzed by independent samples T test.
  4. @Tg values should be considered not correct due to the presence of TgAb in this study.
Back to article page